Trial NCT03430063

View at ClinicalTrials.gov 
Org. Study IDs: R2810-ONC-1763
Secondary IDs: 2017-003684-35

Last trial update was posted on 2022-11-03

MeSH Interventions

Cemiplimab Ipilimumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung

Other Conditions

Advanced Non-Small Cell Lung Carcinoma

Stopping Reasons

Business decision

Limitations And Caveats

All participants' tumors had PD-L1 expression levels of <50% at baseline. Therefore, the results do not present efficacy for participants with PD-L1 expression levels of ≥50% of tumor cells versus all participants.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID